HK1211869A1 - A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) - Google Patents

A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) Download PDF

Info

Publication number
HK1211869A1
HK1211869A1 HK16100004.6A HK16100004A HK1211869A1 HK 1211869 A1 HK1211869 A1 HK 1211869A1 HK 16100004 A HK16100004 A HK 16100004A HK 1211869 A1 HK1211869 A1 HK 1211869A1
Authority
HK
Hong Kong
Prior art keywords
dihydro
oxo
methyl
benzyl
ylmethoxy
Prior art date
Application number
HK16100004.6A
Other languages
English (en)
Chinese (zh)
Inventor
Manja FRIESE-HAMIM
Friedhelm BLADT
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1211869A1 publication Critical patent/HK1211869A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16100004.6A 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc) HK1211869A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12007494.3 2012-11-02
EP12007494 2012-11-02
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (1)

Publication Number Publication Date
HK1211869A1 true HK1211869A1 (en) 2016-06-03

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100004.6A HK1211869A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Country Status (26)

Country Link
US (1) US20150283137A1 (cg-RX-API-DMAC7.html)
EP (1) EP2914264B1 (cg-RX-API-DMAC7.html)
JP (1) JP6255028B2 (cg-RX-API-DMAC7.html)
KR (1) KR102131588B1 (cg-RX-API-DMAC7.html)
CN (1) CN104768553A (cg-RX-API-DMAC7.html)
AR (1) AR093318A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013339823B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008279A2 (cg-RX-API-DMAC7.html)
CA (1) CA2890273C (cg-RX-API-DMAC7.html)
DK (1) DK2914264T3 (cg-RX-API-DMAC7.html)
ES (1) ES2646913T3 (cg-RX-API-DMAC7.html)
HK (1) HK1211869A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20171295T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035483T2 (cg-RX-API-DMAC7.html)
IL (1) IL238536B (cg-RX-API-DMAC7.html)
LT (1) LT2914264T (cg-RX-API-DMAC7.html)
MX (1) MX354518B (cg-RX-API-DMAC7.html)
NO (1) NO2914264T3 (cg-RX-API-DMAC7.html)
PL (1) PL2914264T3 (cg-RX-API-DMAC7.html)
PT (1) PT2914264T (cg-RX-API-DMAC7.html)
RS (1) RS56485B1 (cg-RX-API-DMAC7.html)
RU (1) RU2650679C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201503214YA (cg-RX-API-DMAC7.html)
SI (1) SI2914264T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014067610A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503924B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016002932B1 (pt) 2013-08-14 2021-02-23 Yugenkaisha Japan Tsusyo sistema de cultivo hidropônico
HRP20231548T1 (hr) * 2019-07-10 2024-03-15 Merck Patent Gmbh Farmaceutski pripravak
EP4045009A4 (en) 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
CA2949515C (en) * 2009-01-08 2018-10-23 Axel Becker Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
CN104768553A (zh) 2015-07-08
MX2015005265A (es) 2015-07-17
MX354518B (es) 2018-03-08
RS56485B1 (sr) 2018-01-31
RU2015120692A (ru) 2016-12-27
JP2015536957A (ja) 2015-12-24
CA2890273A1 (en) 2014-05-08
ZA201503924B (en) 2020-11-25
DK2914264T3 (en) 2017-09-11
SG11201503214YA (en) 2015-05-28
EP2914264B1 (en) 2017-08-09
IL238536A0 (en) 2015-06-30
EP2914264A1 (en) 2015-09-09
BR112015008279A2 (pt) 2017-07-04
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
PL2914264T3 (pl) 2017-12-29
AR093318A1 (es) 2015-05-27
HRP20171295T1 (hr) 2017-10-20
ES2646913T3 (es) 2017-12-18
RU2650679C2 (ru) 2018-04-17
KR102131588B1 (ko) 2020-07-08
LT2914264T (lt) 2017-11-10
NO2914264T3 (cg-RX-API-DMAC7.html) 2018-01-06
IL238536B (en) 2019-01-31
AU2013339823A1 (en) 2015-06-18
US20150283137A1 (en) 2015-10-08
WO2014067610A1 (en) 2014-05-08
AU2013339823B2 (en) 2018-01-04
HUE035483T2 (hu) 2018-05-02
CA2890273C (en) 2021-10-26
PT2914264T (pt) 2017-11-14
JP6255028B2 (ja) 2017-12-27

Similar Documents

Publication Publication Date Title
AU2013234767B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with other anti-tumor compounds
AU2015360006B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
US20190388423A1 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an EGFR inhibitor
EP2914264B1 (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
AU2013329865B2 (en) Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
CN105848658A (zh) 具有抗癌活性的6-氧代-1,6-二氢-哒嗪衍生物与吉非替尼的组合
HK1227693A1 (en) Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib
CN105873591A (zh) 用于治疗肾细胞癌(rcc)的6-氧代-1,6-二氢-哒嗪衍生物